首頁 > 市場調查報告書 > 製藥

癌症生物製劑

全球癌症免疫療法市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023年至2030年預測

市場調查報告書

商品編碼

1306946

全球癌症免疫療法市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023年至2030年預測

Global Cancer Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年06月01日 | 出版商:

Value Market Research | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

據預測，到2030年，全球癌症免疫治療市場需求將從2022年的1170.9億美元成長至2369.3億美元，2023-2030年的年複合成長率將達到9.21%。

癌症免疫療法，或免疫腫瘤學，是指利用人體免疫系統的非凡能力來對抗癌症的一種治療方法。免疫系統是人體抵禦包括癌症在內的各種疾病的固有防禦機制。它由各種細胞、組織和器官組成，共同識別並消滅異常細胞，包括癌細胞。

市場動態：

癌症免疫療法市場的大幅成長有幾個關鍵因素。首先，全球癌症發病率不斷上升，推動了對有效治療方案的需求。免疫療法具有靶向各類癌症的潛力，已成為一種前景廣闊的解決方案。其次，免疫療法的良好臨床效果，包括提高生存率和長期療效，促進了免疫療法的應用。第三，免疫療法技術的進步，如新型靶點的發現和聯合療法的開發，提高了治療效果。政府計劃、資金支持和簡化的監管流程也在推動市場成長方面發揮了重要作用。此外，製藥公司與研究機構之間的合作和夥伴關係也加速了該領域的創新。投資的增加和市場競爭的加劇促進了多種免疫治療藥物的開發。針對不同患者量身定做治療方案的個性化醫療方法進一步推動了市場的發展。此外，免疫治療藥物的適應症和批准範圍的擴大也拓寬了潛在的患者人群。總體而言，這些因素加上進行的研究和技術進步，預計將推動癌症免疫療法市場的持續成長。

研究涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰了解行業結構，評估全球競爭吸引力。此外，這些工具還對全球癌症免疫療法市場的各個細分市場進行了全面評估。癌症免疫療法行業的成長和趨勢為本研究提供了一個全面的方法。

區域分析：

這部分涵蓋了區域前景，突出了北美、歐洲、亞太、拉丁美洲以及中東和非洲地區癌症免疫療法市場的當前和未來需求。此外，這部分還重點分析了所有主要地區各個應用領域的需求、估計和預測。

本研究還涵蓋了市場主要參與者的綜合概況以及全球競爭格局的深入分析。 The major players in the cancer immunotherapy market include Pfizer Inc, AstraZeneca, Merck & Co., Inc; F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc; Immunocore, Ltd。本部分包括競爭格局的整體視圖，其中包括各種戰略發展，如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品上市和其他發展。

如果您有任何客製化要求，請聯繫我們。我們的研究團隊可以根據您的需求提供客製化服務。

簡介- 市場動態
市場驅動因素
市場限制因素
市場機會
行業趨勢
波特五力分析
市場吸引力分析
- 市場吸引力分析：按產品分類
- 市場吸引力分析：按應用
- 市場吸引力分析：按配銷通路
- 市場吸引力分析：按最終用途
- 市場吸引力分析：按地區

第4章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料製造商列表
- 主要原料價格走勢
潛在買家名單
行銷管道
- 直接行銷
- 間接行銷
- 行銷管道發展趨勢

第5章：全球癌症免疫療法市場分析：按產品分類

產品概述
歷史和預測資料
按產品分析
單克隆抗體
免疫調節劑
溶瘤病毒療法和癌症疫苗

第6章：全球癌症免疫療法市場分析：按應用分類

概述：按應用
歷史和預測資料
分析：按應用
肺癌
乳腺癌
大腸癌
黑色素瘤
前列腺癌
頭頸部癌症
卵巢癌
胰腺癌
其他癌症

第7章：全球癌症免疫療法市場分析：按銷售管道分類

配銷通路概述
歷史和預測資料
按銷售管道分析
醫院藥房
零售藥店
網路藥店

第8章：全球癌症免疫療法市場分析：按最終用途分類

按最終用途概述
歷史和預測資料
按最終用途分析
醫院和診所
癌症研究中心
其他

第9章：全球癌症免疫療法市場分析：按地域分類

地區展望
產品介紹
北美銷售分析
- 概述、歷史和預測資料銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測資料銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測資料銷售分析
- 亞太地區細分市場銷售分析
- 亞太地區各國銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 亞太其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測資料銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測資料銷售分析
- 中東及非洲各細分市場銷售分析
- 中東及非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第10章癌症免疫治療企業競爭格局

癌症免疫療法市場競爭
夥伴關係/合作/協議
合併與收購
新產品上市
其他發展

第11章：公司概況

公司佔有率分析
市場集中率
Pfizer Inc
- 公司概況
- 公司收入
- 產品
- 近期發展
AstraZeneca
- 公司概況
- 公司收入
- 產品
- 近期發展
Merck & Co. Inc
- 公司概況
- 公司收入
- 產品
- 近期發展
F. Hoffmann-La Roche Ltd
- 公司概況
- 公司收入
- 產品
- 近期發展
Bristol-Myers Squibb Company
- 公司概況
- 公司收入
- 產品
- 近期發展
Novartis AG
- 公司概況
- 公司收入
- 產品
- 近期發展
Lilly
- 公司概況
- 公司收入
- 產品
- 近期發展
Johnson & Johnson Services Inc
- 公司概況
- 公司收入
- 產品
- 近期發展
Immunocore Ltd
- 公司概況
- 公司收入
- 產品
- 近期發展

注-在公司概況中，財務細節和近期發展視情況而定，如果是私營公司則可能不包括在內。

簡介目錄圖表

Product Code: VMR112111378

The global demand for Cancer Immunotherapy Market is presumed to reach the market size of nearly USD 236.93 BN by 2030 from USD 117.09 BN in 2022 with a CAGR of 9.21% under the study period 2023 - 2030.

Cancer immunotherapy, or immuno-oncology, refers to a treatment approach that utilizes the remarkable capabilities of the body's immune system to combat cancer. The immune system serves as the body's inherent defence mechanism against various diseases, including cancer. It consists of various cells, tissues, and organs that work together to identify and destroy abnormal cells, including cancer cells.

MARKET DYNAMICS:

The cancer immunotherapy market is witnessing significant growth due to several key factors. First, there is a rising incidence of cancer worldwide, driving the demand for effective treatment options. Immunotherapy, with its potential to target various types of cancers, has emerged as a promising solution. Second, the favourable clinical outcomes of immunotherapy, including improved survival rates and long-term outcomes, have boosted its adoption. Third, advancements in immunotherapy techniques, such as the discovery of novel targets and the development of combination therapies, have enhanced treatment efficacy. Government initiatives, funding support, and streamlined regulatory processes have also played a crucial role in fueling market growth. Furthermore, collaborations and partnerships between pharmaceutical companies and research institutions have accelerated innovation in the field. Increased investment and market competition have resulted in the development of diverse immunotherapeutic agents. The personalized medicine approach, where treatments are tailored to individual patients, has further propelled the market. Additionally, expanded indications and approvals of immunotherapeutic agents have widened the potential patient population. Overall, these factors, coupled with ongoing research and technological advancements, are expected to drive continued growth in the cancer immunotherapy market.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer immunotherapy. The growth and trends of cancer immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cancer immunotherapy market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Monoclonal Antibodies
Immunomodulators
Oncolytic Viral Therapies & Cancer Vaccines

By Application

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By End Use

Hospitals & Clinics
Cancer Research Centers
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cancer Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer immunotherapy market include Pfizer Inc, AstraZeneca, Merck & Co., Inc; F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc; Immunocore, Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

1 . PREFACE

1.1. Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CANCER IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By End Use
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
5.5 Immunomodulators Historic and Forecast Sales by Regions
5.6 Oncolytic Viral Therapies & Cancer Vaccines Historic and Forecast Sales by Regions

6 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Lung Cancer Historic and Forecast Sales by Regions
6.5 Breast Cancer Historic and Forecast Sales by Regions
6.6 Colorectal Cancer Historic and Forecast Sales by Regions
6.7 Melanoma Historic and Forecast Sales by Regions
6.8 Prostate Cancer Historic and Forecast Sales by Regions
6.9 Head & Neck Cancer Historic and Forecast Sales by Regions
6.10. Ovarian Cancer Historic and Forecast Sales by Regions
6.11 Pancreatic Cancer Historic and Forecast Sales by Regions
6.12 Others Historic and Forecast Sales by Regions

7 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacy Historic and Forecast Sales by Regions
7.5 Retail Pharmacy Historic and Forecast Sales by Regions
7.6 Online Pharmacy Historic and Forecast Sales by Regions

8 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY END USE

8.1 Overview by End Use
8.2 Historical and Forecast Data
8.3 Analysis by End Use
8.4 Hospitals & Clinics Historic and Forecast Sales by Regions
8.5 Cancer Research Centers Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Data Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Data Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Data Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Data Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Data Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CANCER IMMUNOTHERAPY COMPANIES

10.1. Cancer Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CANCER IMMUNOTHERAPY INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Pfizer Inc
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. AstraZeneca
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Merck & Co. Inc
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. F. Hoffmann-La Roche Ltd
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Bristol-Myers Squibb Company
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Novartis AG
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Lilly
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Johnson & Johnson Services Inc
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Immunocore Ltd
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments